Journal
NATURE GENETICS
Volume 27, Issue 4, Pages 383-391Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/86882
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA21765, CA51001] Funding Source: Medline
- NIEHS NIH HHS [ES08658] Funding Source: Medline
- NIGMS NIH HHS [U01GM61393, GM32165, U01GM61374, GM60346] Funding Source: Medline
Ask authors/readers for more resources
Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels and responses to half of all oxidatively metabolized drugs. CYP3A activity is the sum activity of the family of CYP3A genes, including CYP3A5, which is polymorphically expressed at high levels in a minority of Americans of European descent and Europeans thereafter collectively referred to as 'Caucasians'). Only people with at least one CYP3A5*1 allele express large amounts of CYP3A5. Our findings show that single-nucleotide polymorphisms (SNPs) in CYP3A5*3 and CYP3A5*6 that cause alternative splicing and protein truncation result in the absence of CYP3A5 from tissues of some people. CYP3A5 was more frequently expressed in livers of African Americans (60%) than in those of Caucasians (33%). Because CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, CYP3A5 may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available